127 related articles for article (PubMed ID: 23009114)
1. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
Flammiger A; Bayer F; Cirugeda-Kühnert A; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
APMIS; 2012 Nov; 120(11):901-8. PubMed ID: 23009114
[TBL] [Abstract][Full Text] [Related]
2. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V; Aaltomaa S; Lipponen P; Isotalo T; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4435-8. PubMed ID: 16334122
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
5. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
6. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
10. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
14. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Mol Urol; 2000; 4(3):171-5;discussion 177. PubMed ID: 11062371
[TBL] [Abstract][Full Text] [Related]
16. Does the size matter?: Prostate weight does not predict PSA recurrence after radical prostatectomy.
Davidson DD; Koch MO; Lin H; Jones TD; Biermann K; Cheng L
Am J Clin Pathol; 2010 Apr; 133(4):662-8. PubMed ID: 20231620
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
18. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
19. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
